Literature DB >> 11493007

Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.

M Groll1, Y Koguchi, R Huber, J Kohno.   

Abstract

The 20 S proteasome core particle (CP), a multicatalytic protease, is involved in a variety of biologically important processes, including immune response, cell-cycle control, metabolic adaptation, stress response and cell differentiation. Therefore, selective inhibition of the CP will be one possible way to influence these essential pathways. Recently, a new class of specific proteasome inhibitors, TMC-95s, was investigated and we now present a biochemical and crystallographic characterisation of the yeast proteasome core particle in complex with the natural product TMC-95A. This unusual heterocyclic compound specifically blocks the active sites of CPs non-covalently, without modifying the nucleophilic Thr1 residue. The inhibitor is bound to the CP by specific hydrogen bonds with the main-chain atoms of the protein. Analysis of the crystal structure of the complex has revealed which portions of TMC-95s are essential for binding to the proteasome. This will form the basis for the development of synthetic selective proteasome inhibitors as promising candidates for anti-tumoral or anti-inflammatory drugs. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493007     DOI: 10.1006/jmbi.2001.4869

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  36 in total

1.  Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro.

Authors:  I R Garrett; D Chen; G Gutierrez; M Zhao; A Escobedo; G Rossini; S E Harris; W Gallwitz; K B Kim; S Hu; C M Crews; G R Mundy
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

2.  A concise, total synthesis of the TMC-95A/B proteasome inhibitors.

Authors:  Brian K Albrecht; Robert M Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-26       Impact factor: 11.205

Review 3.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

Review 4.  Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.

Authors:  Carlos Camps; Vega Iranzo; Roy M Bremnes; Rafael Sirera
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.603

5.  Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.

Authors:  Sanil Bhatia; Viktoria Krieger; Michael Groll; Jeremy D Osko; Nina Reßing; Heinz Ahlert; Arndt Borkhardt; Thomas Kurz; David W Christianson; Julia Hauer; Finn K Hansen
Journal:  J Med Chem       Date:  2018-11-08       Impact factor: 7.446

6.  The carmaphycins: new proteasome inhibitors exhibiting an α,β-epoxyketone warhead from a marine cyanobacterium.

Authors:  Alban R Pereira; Andrew J Kale; Andrew T Fenley; Tara Byrum; Hosana M Debonsi; Michael K Gilson; Frederick A Valeriote; Bradley S Moore; William H Gerwick
Journal:  Chembiochem       Date:  2012-03-01       Impact factor: 3.164

7.  Fundamental reaction pathway for peptide metabolism by proteasome: insights from first-principles quantum mechanical/molecular mechanical free energy calculations.

Authors:  Donghui Wei; Lei Fang; Mingsheng Tang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2013-10-10       Impact factor: 2.991

8.  Scytonemides A and B, cyclic peptides with 20S proteasome inhibitory activity from the cultured cyanobacterium Scytonema hofmanii.

Authors:  Aleksej Krunic; Armelle Vallat; Shunyan Mo; Daniel D Lantvit; Steven M Swanson; Jimmy Orjala
Journal:  J Nat Prod       Date:  2010-11-08       Impact factor: 4.050

9.  Use of RNA interference and complementation to study the function of the Drosophila and human 26S proteasome subunit S13.

Authors:  Josefin Lundgren; Patrick Masson; Claudio A Realini; Patrick Young
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

10.  Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity.

Authors:  Aslamuzzaman Kazi; Sevil Ozcan; Awet Tecleab; Ying Sun; Harshani R Lawrence; Saïd M Sebti
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.